SARS-CoV-2 modulates virus receptor expression in placenta and can induce trophoblast fusion, inflammation and endothelial permeability

Chiara Agostinis1, Miriam Toffoli1, Mariagiulia Spazzapan2, Andrea Balduit1*, Gabriella Zito1, Alessandro Mangogna1, Luisa Zupin1, Tiziana Salvato3, Serena Maiocchi2,4, Federico Romano1, Sergio Crovella5, Francesco Fontana6, Luca Braga4, Marco Confalonieri7, Giuseppe Ricci1,7, Uday Kishore8,9 and Roberta Bulla2

1Institute for Maternal and Child Health, Istituto di Ricovero e Cura a Carattere Scientifco (IRCCS) Burlo Garofolo, Trieste, Italy, 2Department of Life Sciences, University of Trieste, Trieste, Italy, 3Department of Diagnostic, Clinic and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy, 4Functional Cell Biology Group, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, 5Biological Science Program, Department of Biological and Environmental Sciences, College of Arts and Sciences, Qatar University, Doha, Qatar, 6Division of Laboratory Medicine, Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Trieste, Italy, 7Department of Medical, Surgical and Health Science, University of Trieste, Trieste, Italy, 8Biosciences, College of Health, Medicine and Life Sciences, Brunel University of London, London, United Kingdom, 9Department of Veterinary Medicine, United Arab Emirates University, Al Ain, United Arab Emirates

SARS-CoV-2 is a devastating virus that induces a range of immunopathological mechanisms including cytokine storm, apoptosis, inflammation and complement and coagulation pathway hyperactivation. However, how the infection impacts pregnant mothers is still being worked out due to evidence of vertical transmission of the SARS-CoV-2, and higher incidence of pre-eclampsia, preterm birth, caesarian section, and fetal mortality. In this study, we assessed the levels of the three main receptors of SARS-CoV-2 (ACE2, TMPRSS2 and CD147) in placentae derived from SARS-CoV-2 positive and negative mothers. Moreover, we measured the effects of Spike protein on placental cell lines, in addition to their susceptibility to infection. SARS-CoV-2 negative placentae showed elevated levels of CD147 and considerably low amount of TMPRSS2, making them non-permissive to infection. SARS-CoV-2 presence upregulated TMPRSS2 expression in syncytiotrophoblast and cytотrophoblast cells, thereby rendering them amenable to infection. The non-permissiveness of placental cells can be due to their less fusogenicity due to infection. We also found that Spike protein was capable of inducing pro-inflammatory cytokine production, syncytiotrophoblast apoptosis and increased vascular permeability. These events can elicit pre-eclampsia-like syndrome that marks a high percentage of pregnancies when mothers are...
infected with SARS-CoV-2. Our study raises important points relevant to SARS-CoV-2 mediated adverse pregnancy outcomes.

**KEYWORDS**
SARS-CoV-2, ACE2, TMPRSS2, CD147, pregnancy

**Introduction**

COVID-19 pandemic has triggered an explosion of research focusing on host-pathogen interaction mostly due to the urgency of developing, administering and monitoring a range of vaccine candidates (1, 2). While the mode of infection of target cells by SARS-CoV-2 and its modulation of innate and adaptive immune system, together with coagulation pathway, is beginning to unravel, many aspects of the interplay between SARS-CoV-2 and immune system during pregnancy remain unclear. The impact of COVID-19 on pregnant women’s health and fetal development is now being recognised, but the mechanisms and the evidence for vertical transmission of the virus from the mother to the fetus are not well established. No consensus has been reached yet about the percentage of vertical transmission, with recent findings reporting 2-3% of cases (3, 4). Moreover, the risk of pre-term delivery, pre-eclampsia (PE), cesarean section, severe neonatal/perinatal morbidity and mortality has been found to be significantly increased in COVID-19 pregnant women (5–9). COVID-19 patients show a higher incidence of PE (8,1%), as compared with the non-infected mothers (4,4%) (10, 11), independent of preexisting conditions and other risk factors, such as obesity, diabetes and hypertension (12). Similar pathophysiological association has also emerged between COVID-19 and PE, due to endothelial injury, which leads to an overall inflammatory microenvironment, characterized by an increase in serum and placental levels of pro-inflammatory and decrease in anti-inflammatory cytokines, and the pivotal involvement of complement system (13–15).

The infection of host cells by SARS-CoV-2 requires the presence of transmembrane receptor Angiotensin-Converting Enzyme 2 (ACE2) and Type II Transmembrane Serine Protease (TMPRSS2) (16, 17). SARS-CoV-2 may bind to a third alternative receptor, the cluster of differentiation 147 (CD147)/ Extracellular matrix metalloproteinase inducer (EMMPRIN)/ Basigin (BSG) (18). Among the different receptors for the entry of SARS-CoV-2 that were discovered later, CD147 is one of the key surface molecules involved in regulating implantation, invasion and differentiation of human trophoblasts (19). CD147 is a widely expressed membrane protein of the immunoglobulin superfamily that has been implicated in tissue remodeling and in pathological conditions such as atherosclerosis, aneurysm, heart failure, osteoarthritis, and cancer (20). Furthermore, it is involved in HIV-1 infection by interacting with virus-associated cyclophilin A (21), and in other viral infections, especially SARS-CoV-2 infection. CD147 mediates macrophage activation that results in the expression of matrix metallopeptidase-9, and pro-inflammatory cytokines and chemokines in endothelial cells (22, 23).

SARS-CoV-2 entry receptors, such as CD147 and ACE2, are thought to allow the virus to enter the cell cytoplasm and activate the NLRP3 inflammasome, resulting in the cleavage of interleukin (IL)-1β and IL-18 cytokines (18). SARS-CoV-2 binds ACE2, then TMPRSS2 primes the SARS-CoV-2 Spike protein which subsequently allows the membrane fusion and the entry into the host cell (16, 24). Immunohistochemical analyses in placenta exposed to maternal SARS-CoV-2 demonstrated strong expression of ACE2 in syncytiotrophoblast and cytotrophoblast across gestation, but a weak expression of TMPRSS2, most often confined to the fetal endothelium or unquantifiable by conventional immunohistochemical methods (25). This differential expression of ACE2 and TMPRSS2 is likely responsible for the ongoing debate on the vertical transmission of SARS-CoV-2. Indeed, some placentae lack colocalization of ACE2 and TMPRSS2 (26–28). Another important aspect rendering pregnant women more susceptible to severe COVID-19 is the capacity of SARS-CoV-2 to reduce ACE2 expression in placenta (7). Since ACE2 plays an important role in the regulation of maternal hemodynamics and the development of the placenta (29, 30), its reduced level can become a risk factor for both mother and fetus, resulting in impaired placental vascularity, increased maternal blood pressure, and adverse pregnancy outcomes with placental dysfunction, which can also aggravate pre-existing conditions in pregnant women, such as chronic hypertensive disorders, chronic renal disease, diabetes and pulmonary comorbidities (30–33).

There is therefore a lack of information on how maternal infection with SARS-CoV-2 impacts the expression of ACE2 and TMPRSS2 in the placenta. Here, we compared term placenta collected before the COVID-19 pandemic and SARS-CoV-2+ placentae, analyzing the expression of ACE2, TMPRSS2 and CD147. Receptor expression was investigated also in isolated placental cells and cell lines by Real-Time (RT)-qPCR, Western
blot and flow cytometry. Finally, we evaluated the effects of cell stimulation with Spike protein and SARS-CoV-2 capability to infect placental cells in vitro.

**Materials and methods**

**Reagents and antibodies**

The following antibodies were used: rabbit polyclonal anti-ACE2 (#SAB2100025), anti-mouse polyclonal Immunoglobulins (IgG, IgA, IgM) alkaline phosphatase (AP)-conjugate and antirabbit IgG AP-conjugate were purchased from Sigma-Aldrich (St. Louis, MO, USA); rabbit monoclonal anti-TMPRSS2 (#PA5-116054), rabbit monoclonal anti-CD147 (#MA5-29060), anti-mouse IgG Alexa Fluor® 488-conjugate, Alexa Fluor® 568 phalloidin (#A12380), and V5 Tag Monoclonal Antibody Alexa Fluor 488-conjugate (#37-7500-A488) were bought from Invitrogen; SARS-CoV/SARS-CoV-2 (COVID-19) spike antibody (#GTX632604) was purchased from GeneTex, while anti-SARS/SARS-CoV-2 Coronavirus Nucleocapsid Antibody (#MA1-7403) was from Thermo Fisher Scientific. SARS-CoV-2 Spike protein S1 (aa 1-674) Recombinant antigen was bought from Merck Millipore (Darmstadt, Germania). All other chemicals were purchased from Sigma-Aldrich.

**Tissue samples**

Term placental tissues were obtained from 7 control healthy women and 8 SARS-CoV-2+ women after delivery. Patients’ characteristics are summarised in Table 1.

Placental and decidual biopsy specimens were obtained from women undergoing elective termination of pregnancy at 8-12 weeks of gestation, or from term subjects undergoing caesarean delivery.

The study was approved by the institutional review board of The Maternal-Children’s Hospital (RC 40/20, IRCCS “Burlo Garofolo,” Trieste, Italy), and informed consent was obtained from the participating patients.

**Cell lines**

JAR and BeWo cells were purchased from American Type Culture Collection (ATCC). HTR-8/SVneo was kindly donated by Prof. P.K. Lala (University of Western Ontario, Canada). This cell line was derived from placental villi of the first trimester immortalized by pSV3-neo containing the regions of the SV40 coding for the SV3 Tag. All other placental cell lines were cultured in RPMI 1640 + Glutamax Medium supplemented with 1% v/v penicillin–streptomycin (PS, Sigma-Aldrich) and 10% v/v fetal bovine serum (FBS, Life Technologies). For JAR cell line, a coating of 50 µg/mL fibronectin (Sacco) was needed. Vero E6 cell line (ATCC CRL-1586) was grown in MEM + 10% FBS.

**Cell isolation and culture**

Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords of healthy placenta following the protocol by Jaffe rom (34) and cultured with Human Endothelial Serum-Free Medium (HESFM, Life Technologies, Carlsbad, CA, USA) supplemented with 20 ng/mL of epidermal growth factor (EGF), 10 ng/mL of basic fibroblast growth factor (bFGF) (Immunological Sciences), 1% PS (Sigma-Aldrich) and 10% FBS (Life Technologies). Decidual stromal cells (DSCs) and Decidual endothelial cells (DECs) were isolated from first trimester decidual biopsy specimens as previously described (35). Cells were respectively cultured in RPMI 1640 + Glutamax Medium supplemented with 1% PS and 10% FBS, and HESFM supplemented with 20 ng/mL of EGF, 10 ng/mL of bFGF (Immunological Sciences), 1% PS and 10% FBS. For DECs, a coating with 50 µg/mL fibronectin was needed. Extravilous trophoblasts (EVTs) were purified from placental tissue incubated in Hanks’ balanced salt solution (HBSS) containing 0.25% trypsin and 0.2 mg/mL DNase I (Roche) for 20 min at 37°C. Cells were seeded on 25-cm² flask pre-coated with 5 µg/cm² fibronectin and cultured with RPMI 1640 +Glutamax Medium supplemented with 1% PS and 10% FBS, and used within 12 h.

**TABLE 1 Clinical characteristics of women enrolled in the study.**

| Characteristics            | SARS-CoV-2+ (n=8) | Healthy controls (n=7) |
|----------------------------|------------------|-----------------------|
| Mean maternal age, years (SD) | 34 (3.8)         | 35 (0.7)              |
| Gestational age at delivery, weeks (SD) | 36.4 (4.6) | 37.6 (3.8) |
| Mode of delivery            |                  |                       |
| Vaginal delivery, % (n)     | 0% (0)           | 71.4% (5)             |
| Cesarean section, % (n)     | 100% (8)         | 28.6% (2)             |
| Pregnancy complications     |                  |                       |
| Pre-eclampsia, % (n)        | 0% (0)           | 0% (0)                |
| COVID-19 manifestations     |                  |                       |
| Asymptomatic, % (n)         | 25% (2)          | n.a.                  |
| Paucisymptomatic, % (n)     | 75% (6)          | n.a.                  |
| - Fever ≤37.5°C, % (n)      | 100% (6)         | n.a.                  |
| - Cough, % (n)              | 100% (6)         | n.a.                  |
| - Loss of smell and taste, % (n) | 66.6% (4) | n.a.                  |

SD, standard deviation; n, number; n.a., not applicable.
Immunohistochemical analysis

Term Placental tissues from SARS-CoV-2+ women and control tissues from non-infected healthy mothers were fixed in 10% buffered formalin, paraffin-embedded and stored at 4°C. Sections were deparaffinized with xylene and rehydrated with decreasing concentrations of ethanol (100%, 95%, 70%) and dH2O. To perform antigen retrieval, sections were kept for 20 min at 95°C in Citrate buffer, pH 6, or in Tris-HCl/EDTA buffer, pH 9. Neutralization of the endogenous peroxidase was performed adding H2O2 for 5 min, and then, the sections were incubated with PBS + 2% BSA for 30 min to block non-specific binding. Next, the following antibodies were incubated overnight at 4°C anti-ACE2 (1:200), anti-TMPRSS2 (1:50), anti-CD147 (1:2500) and anti-SARS-CoV–2 spike (1:200) antibodies. Anti-rabbit horseradish peroxidase (HRP)-conjugate (1:500) and anti-mouse HRP-conjugate (1:250) were then incubated for 30 min at RT, prior to detection using AEC kit (Vector Laboratories). Sections were counterstained with Mayer’s haematoxylin (DiaPath) and examined under a Leica DM 2000 optical microscope. Images were collected using a Leica DFC 7000 T digital camera (Leica Microsystems, Wetzlar, Germany).

To quantify the expression of entry receptors in placenta, we utilized an immunoreactive score (IRS), which is commonly used for immunohistochemical evaluation (36). For each slide, we analyzed three different visual fields of the microscope, attributing a score of positivity ranging from 0 to 4.

Real time quantitative PCR

Cells (EVT, DEC, DSC, JAR, BeWo, HTR8 or HUVEC) were grown into a 24-well plate under resting conditions, and/or stimulated with SARS-CoV-2 Spike S1 recombinant protein (10 ng/mL and 1000 ng/mL). Total RNA was isolated using a RNA purification kit (Norgen Biotek company, Thorold, ON, Canada). The isolation of RNA from tissue samples was carried out using Phenol-Chloroform extraction method, and RNA quantification was done via NanoDrop® spectrometer (NanoDrop). RNA was converted to cDNA using SensiFAST™ cDNA Synthesis Kit (Meridian Bioscience, Memphis, TN, USA). The expression level of the following genes was evaluated: ACE2, TMPRSS2, CD147, IL-6, IL-8 and TNF-α. The sequences of the primers used are included in Table 2. The reaction was performed by the Rotor-Gene 6000 (Corbett, Explera), via 45 cycles of denaturation (60 sec at 95°C), annealing (30 sec at 60°C, melting temperature of the primers) and amplification (60 sec at 72°C). The expression level of the different genes analysed was then evaluated via a comparative quantification using Rotor Gene 1.7 Software (Corbett Research) and normalized with the expression of the housekeeping genes (18S, GAPDH and ACTB) (37). To evaluate the viral replication in cells, the CDC primers and probe for N gene (Eurofins, Luxembourg) and the Luna® Universal Probe One-Step RT-qPCR Kit (New England Biolabs, Ipswich, MA, USA) were used via the 7500 Fast Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA, USA) following the cycle of 50°C for 10 min, 95°C for 1 min, and then 40 cycles at 95°C for 10 min, 60°C for 30 min. Standard curve for quantification was generated using the nCoV-CDC-Control Plasmid (Eurofins).

Western blot analysis

To assess the protein level of ACE2, TMPRSS2 and CD147, 1.2 x 10⁶ cells (JAR, BeWo, HTR8 or HUVEC) were lysed. Proteins were then separated via 10% SDS-PAGE under reducing conditions and transferred to a nitrocellulose membrane using the semi-dry Trans-blot Turbo Transfer System (BIORAD). A blocking step with 5% skimmed milk in Tris-Buffered Saline + Tween 20 (TBST, 10 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20) was followed by an overnight incubation at 4°C with primary antibody anti-ACE2 (1:1000), anti-TMPRSS2 (1:1000) and anti-CD147 (1:1000). After washing the membrane three times in TBST, the blot was incubated with anti-rabbit LI-COR IRDye 800CW (1:10000) for 1 h at RT. Another washing step was performed, and the fluorescence intensity was acquired using Odyssey®-CLx near-infrared scanner (LI-COR Biosciences, Lincoln, NE, USA) and processed with Image Studio Ver 5.2 (LI-COR Bioscience). Data were normalized for the signal of β-Actin.

Flow cytometry

4 x 10⁵ cells (JAR, BeWo, HTR8 or HUVEC) were incubated with primary antibodies- anti-ACE2 (1:100), anti-TMPRSS2 (1:100), anti-CD147 (1:100) diluted in dPBS + 2% BSA, 0.7 mM CaCl2 and 0.7 mM MgCl2 for 45 min on ice. Incubation with anti-rabbit FITC-conjugate was performed for 30 min on ice in the dark. The cells were then resuspended and fixed in 1% paraformaldehyde (PFA). The same number of cells were also analyzed following an initial fixation step with 3% PFA in the dark for 20 min. Fluorescence was acquired with the FACScalibur (BD Bioscience, San Jose, CA, USA), and the data was processed using FlowJo™ v 10.7.2 Software (BD Life Sciences).

Evaluation of apoptosis

To evaluate the level of apoptosis induced by SARS-CoV-2, the CellEvent Caspase 3/7 Detection Reagent (ThermoFisher) was used. Cells (JAR, BeWo, HTR8 or HUVEC) were seeded in a 96 well-plate and allowed to reach 80% confluence. Cells were then stimulated with recombinant SARS-CoV-2 Spike S1 protein (10
ng/mL or 1000 ng/mL); H2O2 was used as a positive control. After 6 h, 5 mM CellEvent reagent was added to the wells and incubated for 30 min. The CellEvent reagent is four-amino acid peptide (DEVD)-conjugated to a nucleic acid-binding dye: activated caspases 3/7 cleave the DEVD peptide allowing the dye to bind to DNA and produce a fluorescent emission (~530 nm). Fluorescence intensity was then measured by an INFINITE200 (TECAN).

**Measurement of receptor expression on the membrane**

Placental cells (JAR, BeWo, HTR8 or HUVEC) were cultured in a 96 well-plate (Corning) and allowed to reach 100% of confluence to perform an ELISA on the whole cells. Cells were stimulated overnight with SARS-CoV-2 Spike Protein S1 (10 ng/mL or 1000 ng/mL). Next day, cells were incubated with primary antibodies against SARS-CoV-2 receptors diluted in PBS + 2% BSA + 0.7 mM CaCl₂ + 0.7 mM MgCl₂ for 90 min at RT. Secondary antibody AP-conjugate were then incubated for 1h at RT. pNPP (ChemCruz) solution was added and the absorbance was read at 405 nm using a plate reader (PowerWaveX, BioTek Instruments).

**Evaluation of placental cell susceptibility to SARS-CoV-2 infection in vitro**

Infection experiments were carried out in the BSL-3 laboratory of San Polo Hospital ASUGI (Monfalcone, GO, Italy). SARS-CoV-2 virus, derived from nasopharyngeal swab (beta and delta variant), expanded and isolated from Vero E6 cells, was employed in the experiment. Vero E6 cells, which are highly permissive to SARS-CoV-2 replication, were used as a positive control. Vero E6, HUVECs, HTR-8/SVneo, JAR and BeWo cells were seeded in a 24 well-plate a day prior to setting up infection assay in order to obtain a 70-80% of confluence. SARS-CoV-2 was diluted in serum-free medium and added to the cells at a multiplicity of infection (MOI) of 0.4. After 1 h incubation at 37°C, the medium was removed, cells were washed with PBS and fresh medium was added. Vero E6 cells, which are highly permissive to SARS-CoV-2 replication, were used as a positive control. Vero E6, HUVECs, HTR-8/SVneo, JAR and BeWo cells were seeded in a 24 well-plate a day prior to setting up infection assay in order to obtain a 70-80% of confluence. SARS-CoV-2 was diluted in serum-free medium and added to the cells at a multiplicity of infection (MOI) of 0.4. After 1 h incubation at 37°C, the medium was removed, cells were washed with PBS and fresh medium was added. Vero E6 cells, which are highly permissive to SARS-CoV-2 replication, were used as a positive control.

**TABLE 2 Primer sequences used for RT-qPCR.**

| Protein | Gene | Sense | Gene Sequence (5' → 3') | Tm (°C) | NCBI GeneID |
|---------|------|-------|-------------------------|--------|-------------|
| Angiotensin Converting Enzyme 2 | ACE2 | Forward | ACAGTCCACACCCATGGGGTC | 60 | NM_001371415.1 |
| | | Reverse | TGGAGGACTGAGAAGACCCAT | | |
| Transmembrane Serine Protease 2 | TMPRSS2 | Forward | GAT TAG CCG TCT GCC TCT ATT TGT | 58 | NM_001135099.1 |
| | | Reverse | CAG GAG TGT AGC GGA ATG TGA TGG | | |
| BSG basigin | CD147 | Forward | CTA GAC ATG GAC AAG CTC AAC | 60 | NM_001728.4 |
| | | Reverse | TTC TCT GTG ATG AAC ATG ATG | | |
| Interleukin 6 | IL-6 | Forward | GTA CAT CCT CGA CGG CAT C | 60 | NM_000600.3 |
| | | Reverse | CCA GCC AAG TCT CCT CAT TG | | |
| C-X-C motif chemokine ligand 8 | IL8/CXCL8 | Forward | AGG TGC AGT AGT TTT GCC AAG GA | 60 | NM_000584 |
| | | Reverse | TTT CTG TGT TGG GCC AGT GT | | |
| Tumor Necrosis Factor-α | TNF | Forward | GGC CCA GCC AGT CAG ATC AT | 65 | NM_000594.3 |
| | | Reverse | GGG CTC CTG GAT GCC AGA GA | | |
| C-C motif chemokine ligand 2 | MCP1/CCL2 | Forward | ATC AAT GCC CCA GTC ACC | 60 | NM_002982.3 |
| | | Reverse | AGT CTT CGG AGT TTG GG | | |
| CCL5 C-C motif chemokine ligand 5 | RANTES/CCL5 | Forward | CAT CAT GAA GGT CTC CGC | 60 | NM_002985.3 |
| | | Reverse | GAC GAA GAC GAC TCG TGG | | |
| C-X-C motif chemokine ligand 10 | IP10/CXCL10 | Forward | AGG AAC CTC CAG TCT CAG CA | 60 | NM_001565.4 |
| | | Reverse | CAA AAT TGG CCT GCA GTA ATG | | |
| Ribosomal protein S18 | RPS18 | Forward | ATC CCT GAA AAG TTC CAG CA | 60 | NM_022551.2 |
| | | Reverse | CCC TGT TGG TGA GGT CAA TG | | |
| Actin Beta | ACTB | Forward | CTA CAA TGA TGT CCG TGT G | 60 | NM_001101.3 |
| | | Reverse | AAG GAA GGC TGG AAG AGT GC | | |
| Glyceraldehyde-3-phosphate dehydrogenase | GAPDH | Forward | GAT CAT CAG CAA TGG CTC CT | 60 | NM_002046.5 |
| | | Reverse | GT GAT CAT GAG TTC CTC CA | | |
| SARS-CoV-2 Nucleocapsid Protein | 2019-nCoV_N2 | Forward | TTA CAA ACA TTG GCG GCA AA | 43740575 |
| | | Reverse | GGG CGA CAT TCC GAA GAA | | |
| | | Probe | FAM-ACA ATT TGC CCC CAG GGC TTC AG-BHQ1 | | |

ng/mL or 1000 ng/mL; H2O2 was used as a positive control. After 6 h, 5 μM CellEvent reagent was added to the wells and incubated for 30 min. The CellEvent reagent is four-amino acid peptide (DEVD)-conjugated to a nucleic acid-binding dye: activated caspases 3/7 cleave the DEVD peptide allowing the dye to bind to DNA and produce a fluorescent emission (~530 nm). Fluorescence intensity was then measured by an INFINITE200 (TECAN).
distilled water and subjected to thermolysis for RNA extraction (98°C for 3 min and 4°C for 5 min). The viral load was then quantified by RT-qPCR.

To assess if pre-treatment of the cells can improve the susceptibility towards the infection, cells were challenged with SARS-CoV-2 for 24 h (MOI=0.4). After washing, cells were challenged with the virus (MOI=0.4) for 1 h and the viral load was measured at day 1 and at day 4 post infection, as described above.

Cell transfection with delta spike and cell fusion assays

BeWo, JAR, HTR-8/SVneo and HUVEC cells were incubated for 24 h with SARS-CoV-2 (MOI=0.4). Next, cells were washed in PBS, lysed, and RNA was isolated by the total RNA purification kit (Norgen Biotek company, Thorold, ON, Canada). JAR and HTR-8/SVneo cells were seeded at 1.2 x 10^4 cells/well in a 96-well plate (CellCarrierUltra, Optical Plate, PerkinElmer). After 10 h, cells were transfected with: (a) pCMV-SPIKEDelta-V5 + PCMVC-hACE2; (b) pCMV-SPIKEDelta-V5 + pcDNA3; (c) pCMV-GFP + pcDNA3. For each condition, a transfection mix was prepared with OPTIMEM (Gibco #31985062), FuGENE (Promega, #E2311) and both plasmids at the ratio of 50 μl OPTIMEM: 3.5 μl FuGENE: 1 μg total pDNA. Plasmids in each mix were added at 1:1 ratio. Each transfection mix was incubated at RT for 15 min, then 10 μl of mix was added to each well (200 ng of total DNA per well). The plate was incubated at 37°C under 5% CO2 for 24 h.

Immunofluorescence microscopy

Cells (JAR, BeWo, HTR8 or HUVEC) were seeded onto round glass coverslip of 10 mm diameter and allowed to reach up to 70% confluence. Cells were then fixed with 3% PFA for 15 min in the dark. Blocking, permeabilization and quenching were sequentially carried out using 1% BSA, 0.1% Triton X-100 and 50 mM glycine in PBS, respectively, for 30 min at RT. Primary antibodies diluted in PBS + 2% BSA were added for 1 h, followed by incubation with anti-rabbit Cy3-conjugate (1:300) for 30 min at RT. Nuclei were stained with DAPI. Glass slides were mounted using Fluorescence Mounting Medium (Dako) and images were acquired with various devices as described in the figure legends.

To assess the viral entry at different time points and the transfection after 12 h, cells were fixed and permeabilized as described above. First, the non-specific binding of the antibody was blocked by 1 h of incubation with PBS-T + 10% normal goat serum (NGS). Cells were incubated overnight with anti-SARS/SARS-CoV-2 Coronavirus Nucleocapsid Antibody (1:100 in PBS-T + 1.5% NGS), and then with the anti-mouse Alexa Fluor 488-conjugate (1:500) for 1 h coupled with Alexa Fluor 569-conjugated Phalloidin (1:400). Subsequently, the coverslips were sealed on glass slides with a DAPI mounting medium (Fluoroshield™ with DAPI, Sigma Aldrich, Merck KGaA, Darmstadt, Germany). To evaluate the transfection with Delta Spike, cells were blocked with PBS + 1% BSA for 30 min. The staining for the Spike protein was then performed with anti-V5 Alexa 488 antibody (1:500 in BSA) for 2 h at RT and nuclei were stained with HOECHST 33342 (1:5000 in PBS, Invitrogen). A total of 15 fields per well were acquired and analyzed for the formation of cellular syncitia using the Harmony software (PerkinElmer) (38). Three independent biological replicates were run.

Permeability assay

HUVECs (2 x 10^4 cells) were seeded on to a fibronectin-coated (20 μg/mL) polycarbonate insert in a 24-well transwell (TW) system (6.5 mm diameter, 8-μm pores; Corning Costar, Milan, Italy) and incubated for 4 days, to allow the cells to form a functional monolayer. TWs were then tested for the formation of an intact endothelial monolayer by adding 1 mg/mL FITC-BSA (Sigma-Aldrich) in the upper chamber; the amount of labelled BSA that leaked through to the lower TW chamber was measured by an INFINITE200 (TECAN). When the fluorescence intensity was negligible, the following stimuli were added to the upper chamber: SARS-CoV-2 Spike Protein S1 (Sigma-Aldrich) (10 ng/mL or 1000 ng/mL) or 0.1 μg/mL Histamine (Sigma-Aldrich) as a positive control. The leaking of FITC-BSA was evaluated after 15 and 30 min.

Statistical analysis

Mean and standard deviations were calculated for continuous variables, whereas frequencies and percentages were reported for categorical variables. Non-parametric data were assessed by Mann-Whitney U-tests. Patient data were analyzed by T-Student test. Analysis of different groups of data was performed using two-way analysis of variance (ANOVA). Results were expressed as mean ± standard deviations and p-values <0.05 were considered statistically significant. All statistical analyses were performed using GraphPad Prism software 9.0 (GraphPad Software Inc., La Jolla, CA, USA).

Results

Expression and distribution of ACE2, TMPRSS2 and CD147 in healthy placenta

To elucidate the mechanism of SARS-CoV-2 infection of the placenta, we first evaluated the basal expression and distribution of the main SARS-CoV-2 receptors: ACE2, TMPRSS2 and CD147 (Figure 1A), via immunohistochemistry (IHC) using 5 healthy term placentae.
IHC analysis revealed ACE2 expression on the syncytiotrophoblast monolayer (red arrows), with highly variable intensity (Supplementary Figures 1, 2). The staining for TMPRSS2 expression was either very weak or almost absent, with the exception of some isolated cells in the intervillous space, which are likely polymorphonuclear leukocytes (green arrows). CD147 staining was strong in healthy placental tissues, being mainly present in the brush border of syncytiotrophoblasts. We also evaluated the local gene expression of the receptors, performing RT-qPCR on first and third trimester placental tissues as well as isolated placental cells. As shown in Figure 1B, ACE2 transcript was detected in all the tissue samples analyzed, with higher expression in third trimester placentae. The mRNA expression of CD147 was particularly elevated in first trimester decidua, showing an increase from first to third trimester in placental villi. A similar pattern of increase from first to third trimester villi was observed for TMPRSS2 mRNA. With respect to first trimester isolated placental cells, we observed high expression of ACE2 and CD147 transcripts (Figure 1C) in all cell populations analyzed: EVT, DECs and DSCs. On the contrary, mRNA levels of TMPRSS2 were elevated only in DSC population (Figure 1C).

In summary, in healthy conditions, we noticed a variable expression of ACE2 by trophoblast cells (especially syncytiotrophoblast), a very low presence of TMPRSS2, and a strong expression of CD147.

ACE2, TMPRSS2 and CD147 expression in placental cell lines

In order to further assess the expression of SARS-CoV-2 receptors, we measured their mRNA and protein levels in different placental cell lines: HUVECs, the immortalized cytotrophoblast cell line HTR8/SVneo, and two trophoblast-derived choriocarcinoma cell lines, namely JAR and BeWo. We initially assessed ACE2 mRNA expression by RT-qPCR (Figure 2A), which showed a particularly high expression in HUVECs. However, the presence of the transcript did not correlate with protein level as demonstrated by Western Blot (WB) analysis (Figure 2B and Supplementary Figure 3), which revealed the strongest protein expression of ACE2 in JAR. Flow cytometric analysis (Figure 2C and Supplementary Figure 4A) confirmed WB results, with a higher percentage of ACE2 positive cells in JAR population, both in live and fixed cells (Supplementary Figure 4D). On the contrary, the positivity of BeWo and HTR8SVneo emerged only after fixation (Supplementary Figure 4D).

The above-mentioned inconsistency between mRNA and protein expression levels was observed for TMPRSS2 as well. Figure 2D shows a moderate expression of TMPRSS2 transcript in JAR and HUVECs, whereas the WB analysis highlights a strong synthesis of the co-receptor by HTR8SVneo (Figure 2E and Supplementary Figure 3). In this case, the FACS analysis also showed different results as compared to WB, indicating JAR as the major producer of TMPRSS2 (Figure 2F and Supplementary Figure 4B). Briefly, all the cell lines had low levels of TMPRSS2 protein expression (Figure 2F).

The analysis of CD147 mRNA and protein expression (Figure 2G–I) confirmed previous observations in IHC. The protein was highly expressed by all the cell lines, especially by JAR and BeWo (Figures 2H, I and Supplementary Figure 4C). The expression of ACE2, TMPRSS2 and CD147 proteins was also analyzed by immunofluorescence (IF) (Figures 2J–L). Consistent with IHC, a positive staining for ACE2 in syncytiotrophoblast cells (BeWo) was noted; accordingly, BeWo and JAR cells showed a low positivity for TMPRSS2 and a high expression of CD147.

The expression pattern of ACE2 in placenta is modulated by SARS-CoV-2

To gauge the likely mechanism of SARS-CoV-2 infection of placenta, we initially investigated the presence and distribution of the SARS-CoV-2 Spike protein (S2) in placental tissues derived from eight SARS-CoV-2+ pregnant women. Spike protein was identified with variable intensity of staining among the tissue samples (Supplementary Figures 1B, 5).

To characterize the expression of SARS-CoV-2 receptors in the placenta due to COVID-19, we analyzed the pattern of ACE2, TMPRSS2 and CD147 in placental tissues derived from eight SARS-CoV-2+ pregnant patients, and comparing them with seven healthy placentae (Supplementary Figure 1). ACE2 staining was localized to the cytoplasm of syncytiotrophoblast cells in normal tissues, whereas SARS-CoV-2+ placentae additionally showed ACE2 positivity in fetal vessels of chorionic villi, as shown in Figures 3A, B. As a general trend, we noticed an inverse correlation between the intensity of Spike protein staining and ACE2, even though a statistically significant quantification of this observation was hindered by the low number of samples available (Supplementary Figures 1B, 6).

To mimic in vitro the pathologic condition, we stimulated the placental cell lines with Spike protein (S1) at the concentration of 10 or 1000 ng/ml for 24h. After stimulation, ACE2 mRNA and protein expressions in placental cell lines were analyzed by RT-qPCR (Figure 3C) and live-cell ELISA (Figure 3D). We observed a significant downregulation in ACE2 mRNA levels only in JAR cells treated with 10ng/ml of Spike protein, whereas the protein expression was upregulated in HTR8/SVneo, although the signal was very low.

Surprisingly, we failed to detect the presence of membrane-bound ACE2 on BeWo cells by ELISA, probably due to the intracellular localization of the epitope recognized by the antibody; in this cell line, we found a significant downregulation...
of ACE2 mRNA expression induced by Spike protein at the concentration of 1000 ng/ml (Supplementary Figure 7).

The expression of TMPRSS2 is upregulated in placenta and in placental cells by SARS-CoV-2

The level of TMPRSS2 in infected and uninfected placental tissues was evaluated by IHC. As shown in Figures 4A, B and Supplementary Figure 1, the TMPRSS2 level in SARS-CoV-2+ placental tissues was upregulated compared to placenta from uninfected mothers. Its localization was not limited to the syncytiotrophoblast, but also in the endothelium of villi vessels. In vitro culture of placental cell lines stimulated with the Spike protein validated these observations: trophoblast cells (JAR and HTR8/SVneo) showed an upregulation of TMPRSS2 expression following Spike protein challenge (Figures 4C, D). Surprisingly, BeWo cells, when challenged with Spike protein, showed a significant downregulation of TMPRSS2 mRNA expression.
Expression of CD147 in placenta is upregulated by SARS-CoV-2

The IHC analysis revealed an abundance of CD147 in infected placentae compared to uninfected ones (Figure 5 and Supplementary Figure 1). In vitro evaluation of CD147 protein showed an upregulation induced by Spike protein in BeWo and HUVECs cells (Figure 5).

Evaluation of pathogenetic mechanisms of Spike protein

Since the PE-like syndrome is characterized by an increase in syncytiotrophoblast apoptosis, we stimulated the placental cell lines with Spike protein (S1) at the concentration of 10 or 1000 ng/ml for 24h and explored the potential pro-apoptotic effect of the Spike protein on the cells, using a specific assay that detects the
activation of caspase 3/7. Hydrogen peroxidase was used as a positive control for apoptosis. As shown in Figure 6, BeWo cells showed a slight apoptosis induction with 10 ng/ml of S1 protein, whereas HTR8SVneo required a higher concentration of Spike protein to induce apoptosis. No effects were detected in the other cell populations.
Analysis of the capability of SARS-CoV-2 to infect placental cells

BeWo, JAR, HTR8/SVneo and 5 different populations of HUVECs were challenged with SARS-CoV-2 to assess their susceptibility to viral entry and replication. No morphological cytopathic as well as cytotoxic effects (analyzed by MTT assays) were evident in the cell lines during the 7 days of infection. The RNA viral load was monitored during the infection period, but it remained at the basal level recorded on the day 0 (Figure 7). Vero E6 cell line was used as a positive control of successful infection, observing an increment in the viral RNA levels as compared to placental cell lines (Figure 7). Since a residual quantity of viral RNA was detected in the supernatants, after washing and medium changing, the presence of SARS-CoV-2 was assessed intracellularly using immunofluorescence for the viral nucleocapsid protein; no signal was detected inside the infected cells as compared to Vero E6 cells, where a diffuse staining was detected (Supplementary Figure 8).

The cells were also challenged with SARS-CoV-2 for 24 hours and then incubated with new virus to determine if the pretreatment could enhance the susceptibility of the cells to the infection. Despite the pre-stimulation, no viral replication was detected after 4 days of infection (Supplementary Figure 9), suggesting that placental cells were resistant to SARS-CoV-2 entry in vitro.

Evaluation of the mechanisms of resistance to infection

In order to understand the mechanisms underlying the resistance to SARS-CoV-2 infection by placental cells, we performed transfection with the Spike protein to observe the formation of cellular syncytia. The simultaneous presence of Spike protein and functional receptor-co-receptor combination (ACE2, TMPRSS2) on the cell surface, in fact, led to the activation of fusogenic mechanisms which manifested in the formation of syncytia (Figure 8). Since BeWo cells, by their nature, tend to form syncyia, they were excluded from the analysis. Our results indicated that HTR8/SVneo were more amenable to form cellular syncitia even under basal conditions (Figures 8A, B), whilst JAR cells overexpressing the human ACE2 gene together with SARS-CoV-2 Spike were unable to form syncytial structures at 24 hours post-transfection (Figure 8D), despite showing a similar number of cells positive for SARS-CoV-2-Spike (Figure 8E) as compared to HTR8/SVneo cells. HTR8/SVneo exhibited increase in syncytial structures upon SARS-CoV-2-Spike transfection alone and together with humanACE2 (Figure 8B). Expression levels of SARS-CoV-2-Spike and human ACE2 were assessed by RT-qPCR at 24 hours post-transfection (Figures 8C, F). Vero E6 cell line was used as a positive control (Supplementary Figure 10).

SARS-CoV-2 induced pro-inflammatory cytokine expression in syncytiotrophoblast cells

We next investigated the direct activation induced by intact SARS-CoV-2 in terms of cytokine expression. The placental cells were incubated for 24h with the virus and the cytokine gene expression was investigated by RT-qPCR. As shown in Figure 9, the virus-cell contact induced the upregulation of IL-6, IL-8 and TNF-α in BeWo cells. These data were confirmed by the incubation of placental cells with Spike protein only, as shown in Supplementary Figure 11.

Evaluation of the effects of SARS-CoV-2 and spike protein on endothelial cell activation

Since SARS-CoV-2 infection is responsible for endothelial dysfunction and disruption of vascular integrity, resulting in hyperinflammation and hypercoagulability state (39, 40), we investigated the potential endothelial damage/activation effect on HUVECs. First, we analyzed if the virus could induce the expression of pro-inflammatory/pro-fibrotic chemokines/cytokines. Our results confirmed the role of ECs in cytokine storm; SARS-CoV-2-challenged HUVECs induced a strong upregulation of MCP-1/CCL2 expression and, to a lesser extent, IP-10/CXCL10, IL-8 and TGF-β (Figure 10A).

We also investigated the expression of adhesion molecules VCAM-1 and E-Selectin by HUVECs. We stimulated the cells with 10 or 1000 ng/mL of S1 protein for 18h or 4h respectively and then performed ELISA on whole live cells. TNF-α (100 ng/mL) stimulation was used as a positive control. No exposure of VCAM-1 nor E-Selectin was revealed after Spike stimulation by HUVECs, compared to TNF-α-stimulation (Figure 10B).

Moreover, we performed permeability assay in order to evaluate endothelial monolayer integrity. The results of leakage assay, as shown in Figure 10C, indicated that Spike protein (10 and 1000 ng/mL) was able to increase the permeability with a statistically significant effect after 15 and 30 minutes.

Discussion

SARS-CoV-2 is a novel and deadly coronavirus causing global health concerns among pregnant women. Two years after the outbreak of the pandemic, the maternal-neonatal vertical transmission mechanisms of COVID-19 are yet to be clarified. The association between SARS-CoV-2 infection in pregnancy and the onset of gestational complications are quite well-established (8, 9, 15). Despite isolated cohorts showing a high percentage of vertical transmission, no universal consensus
has been reached yet. More recent meta-analyses showed that about 2-3% of newborns from SARS-CoV-2 positive women were infected (3, 4). Since SARS-CoV-2 positivity in the newborn was shown to be associated with maternal factors (severe COVID 19 manifestations, death and admission to intensive care unit) (4), the variability among different studies may be mainly due to cohort selection and inclusion criteria. In any case, the mechanisms for vertical transmission and the onset of gestational complications are not fully understood.

In the current study, we assessed the expression of SARS-CoV-2 entry receptors in the normal placenta and investigated how this expression was modulated by the virus. It is well...
established that the infection of host cells by SARS-CoV-2 requires the presence of two receptors: ACE2 and TMPRSS2 (16). However, SARS-CoV-2 may bind to a third alternative receptor, the CD147/EMMPRIN/BSG (18), a membrane protein belonging to the immunoglobulin superfamily that has been implicated in tissue remodeling and in pathological conditions such as atherosclerosis, aneurysm, heart failure, osteoarthritis, and cancer (20, 41–43). Among the different receptors identified for the entry of SARS-CoV-2, CD147 is an inducer of matrix metalloproteinases and angiogenic factors, and is expressed in...
the uterus having an important role in embryo implantation (44). It is also one of the key surface molecules involved in regulating invasion and differentiation of human trophoblast (19).

To elucidate the mechanisms of SARS-CoV-2 infection of the placenta, we first evaluated the basal expression and distribution of entry receptors by performing IHC on healthy placentae. ACE2 expression was localized on the syncytiotrophoblast monolayer, although we noticed highly variable intensity among patients, consistent with earlier reports (29, 45, 46). The staining for TMPRSS2 was either very weak or absent, with the exception of some isolated cells in the intervillous space, which are likely to be polymorphonuclear leukocytes, confirming the observations reported in recent studies (26, 27, 47). On the contrary, the intensity of CD147 staining was strong mainly in the brush border of syncytiotrophoblasts, as reported by others.

**FIGURE 6**
Evaluation of the proapoptotic effect of Spike S1 protein on placental cells. JAR (A), BeWo (B), HTR8/SVneo (C) or HUVECs (D) were grown to 80% confluence in 96-well plates and incubated with 10 ng/mL or 1000 ng/mL of Spike S1 protein. H2O2 (0.5 µM) was used as a positive control. The cells were incubated with 5 µM of CellEvent Caspase-3/7 Green Detection Reagent. Fluorescence signals were normalized for the total proteins present in each well. For each group, the line in the middle of the box represents the median. The lower and the upper edges of the box indicate the 1st and 3rd quartile, respectively. Data are results from three independent experiments performed in triplicate. *p < 0.05, as compared to untreated cells (Mann-Whitney test).

**FIGURE 7**
Quantification by RT-qPCR of SARS-CoV-2 RNA presence in the supernatant of cells incubated with the virus. VERO E6 were used as a control. The viral load was displayed as Log_{10} viral copies/ml (mean ± SD) at day 0, 4 and 7 post infection.
We also evaluated the local gene expression of the receptors, by performing RT-qPCR on healthy placental tissues and on isolated primary placental cells. Several studies have analyzed SARS-CoV-2 entry receptors in placenta by molecular pathology methods and placenta-derived cells from a publicly available database and analyzed by bioinformatics (26, 27), reporting that ACE2 and TMPRSS2 are expressed in the placenta during the first trimester, which diminishes across gestational age (28). These data are partly in contrast to our observation regarding the mRNA expression of the receptors. Moreover, previous studies indicated that there was no co-expression or localization of both receptors in the placenta at term (27, 50). Our results showed that EVT, DECs and DSCs expressed a great amount of ACE2 and CD147 transcripts, whereas TMPRSS2 was expressed only by DSCs and, to a lesser extent, by EVT. In 2005, Valdés rom (29) showed that, in placental villi, the main sites of ACE2 expression were the syncytiotrophoblast, cytotrophoblast and endothelium; in decidua, ACE2 was expressed in the invading and intravascular trophoblast as well as in arterial and venous endothelium of the umbilical cord. Taglauer and coworkers identified the abundance of ACE2 expression in comparison with TMPRSS2 (26); virus protein and ACE2 expression consistently localized primarily within the outer syncytiotrophoblast layer of placental villi.

To perform in vitro functional assays, we used the placental cell lines JAR, HTR8/SVneo and BeWo, as models of...
cytotrophoblast and syncytiotrophoblast cells, and HUVECs, the endothelial cells isolated from human umbilical cord vein, as a model of villi endothelium. We performed RT-qPCR, flow cytometry, IF and WB assays, to validate the IHC data: the expression of TMPRSS2 was very low, whereas that of CD147 appeared to be greater. In general, JAR, BeWo and HUVECs showed ACE2 expression.

We performed IHC analyses of the entry receptors on SARS-CoV-2 infected placentae and compared them with healthy placentae. Moreover, to mimic in vitro the effect of SARS-CoV-2 presence in the placenta, we stimulated the cells with Spike protein (S1). A significant pro-apoptotic effect was observed, in BeWo and HTR8/SVneo cell lines, but not in HUVECs and JAR cells. Mourad et al found that the expression level of placental ACE2, but not TMPRSS2, was higher in women with severe COVID-19 (51). However, the study did not analyze infected placentae; only placenta presenting SARS-CoV-2 RNA expressed high levels of TMPRSS2. In our study, stimulation of placental cells with Spike protein resulted in an upregulation of TMPRSS2 in cytotrophoblast cell lines (JAR and HTR8/SVneo), whereas no effects were observed on HUVEC. These results were partially in accordance with IHC analysis of SARS-CoV-2 positive placentae that revealed an increase in TMPRSS2 staining. A significant downregulation of ACE2 mRNA expression was observed in JAR and BeWo; however, this was not confirmed by protein analysis. We also noticed an increase in CD147 staining of SARS-CoV-2 infected placentae compared to non-infected counterparts. Spike protein was able to enhance the expression of CD147 at protein level in all placental cell lines (JAR and BeWo) and HUVEC.

In view of the conflicting reports on the ability of SARS-CoV-2 to infect placental cells SARS-CoV-2 to infect placental cells, since contradictory (52, 53), we challenged the placental cell lines with SARS-CoV-2. No viral replication was observed suggesting that BeWo, JAR, HTR8/SVneo and HUVECs were not permissive to viral infection. SARS-CoV-2 was also not able to enter the cells, since the immuno staining for the viral nucleocapsid protein showed no positivity, and no morphological alterations were observed. Since the treatment of the cells with Spike protein enhanced the expression of ACE2, TMPRSS2 and CD147, cells were first primed with the virus, then new virus was added. However, no viral replication was observed after 4 days. EC infection with SARS-CoV-2 has been
FIGURE 10
Pro-inflammatory effect of SARS-CoV-2 or Spike S1 protein on HUVECs. (A) RT-qPCR for gene expression analysis of MCP-1/CCL2, RANTES/CCL5, IP-10/CXCL10, IL-8/CXCL8, IL-6 and TGF-β in SARS-CoV-2-stimulated HUVECs. After 24 h of treatment with S1, total mRNA was isolated and gene expression analysis was performed by RT-qPCR. The expression was normalized using the housekeeping genes 18S, ACTB and GAPDH; the results were mediated and expressed as fold increase. Data are expressed as mean ± SD of two independent experiments performed in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001, as compared to untreated cells. (B) Analysis of the expression of the adhesion molecules VCAM-1 and E-Selectin. Four different populations of HUVECs were grown to confluence in a 96-well plate and incubated with 10 ng/mL or 1000 ng/mL of Spike S1 protein. TNF-α (100 ng/mL) was used as a positive control. Cells were incubated with anti-human VCAM-1 or anti-human E-selectin monoclonal antibodies, followed by alkaline phosphatase-conjugated secondary antibodies. Data are expressed as mean ± SE of four experiments performed in triplicate. **p < 0.01, as compared to untreated cells (Mann-Whitney test). (C) Permeabilizing effect of Spike protein on endothelial cells. The permeabilizing activity was evaluated kinetically, after 15 and 30 minutes, by adding 10 ng/mL or 1000 ng/mL of Spike protein to the upper chamber of the transwell, and then measuring the amount of FITC-labeled BSA that leaked through a monolayer of endothelial cells into the lower chamber. Histamine (HIS) was used as a positive control. Data are expressed as mean ± SD of four experiments performed in duplicate. *p < 0.05; **p < 0.01, as compared to untreated cells (Mann-Whitney test).
reported under well-defined conditions of culture, such as 3D culture and in vivo studies (54, 55). It is possible that the dysfunction of EC glyocalyx induced by ROS production by SARS-CoV-2-activated leukocytes could facilitate the entry of the virus into ECs.

We carried out transfection with the Spike protein to view the formation of cellular syncytia because the simultaneous presence of Spike and functional co-receptors on the cell surface leads to the activation of fusogenic mechanisms which manifest themselves in the formation of syncytia (56). We found that JAR cells, co-transfected with human ACE2 and SARS-CoV2-Spike constructs, did not form syncytial structures at 24 hours after transfection. As suggested earlier (19, 57) IFN-induced transmembrane proteins (IFITMs), a family of restriction factors blocking the entry step of many viruses, could be involved in the resistance to syncytia formation by trophoblast cells.

Since COVID-19 is characterized by cytokine storm (25, 26), we investigated induction of pro- and anti-inflammatory cytokines by placental cells when challenged with intact SARS-CoV-2 or Spike protein. In particular, BeWo cells showed an upregulation of IL-6, IL-8 and TNF-α when challenged with the intact virus, but they appeared to be less responsive to Spike protein, probably due to the proapoptotic effect induced by the virus protein on these cells. S1 Spike protein on its own was also sufficient to cause increased pro-inflammatory cytokine production: in particular, IL-6 expression was found to be significantly higher in JAR cells challenged with the higher concentration of Spike protein. Thus, placental cells contribute to the cytokine storm induced by SARS-CoV-2 (58). Interestingly, IL-8, a pro-angiogenic factor, was significantly upregulated in HUVECs challenged with the higher concentration of Spike protein.

Evidence that COVID-19 is not merely a pulmonary disease is currently accumulating. In fact, SARS-CoV-2 has a great tropism for several different organs due to wide distribution of ACE2, making COVID-19 a multi-organ disease. One of its main clinical manifestations is endothelial cell dysfunction, causing systemic vasculitis and thrombotic complications (59–61). Among the multiple mechanisms leading to endothelial cell dysfunction, an increase in adhesion molecule expression and vascular permeability in the pulmonary ECs have been reported (40). We therefore investigated the ability of HUVECs, a classical endothelial model system, to respond to Spike stimulation. We first confirmed the pivotal role of ECs in cytokine storm: in fact, SARS-CoV-2 induced a strong upregulation of MCP-1/CCL2 expression, and to a lesser extent, of IP-10/CXCL10, IL-8 and TGF-β in HUVECs. Noteworthy is the up-regulation of TGF-β synthesis, a cytokine considered anti-inflammatory but notoriously involved in fibrosis, a pivotal pathogenetic process in COVID-19. Since SARS-CoV-2 infection is responsible for endothelial dysfunction, we analyzed the ability of the virus to induce activation of EC. However, S1 protein did not alter the adhesion molecules VCAM-1 and E-Selectin exposure by HUVECs. Nevertheless, S1 protein was able to alter endothelial monolayer integrity and make it leakier by increasing cell permeability.

A limitation of this study is that the observations are primarily based on the use of trophoblast cell lines and not on primary trophoblasts isolated from human placentas. Although the cell lines are very useful for obtaining a simple, rapid and reproducible overview of the behavior of the placenta, the results obtained with these lines have not always been confirmed on the primary cells. Another limiting component is that not all the known receptors for the entry of SARS-CoV-2, which would have given a better overview of the possibility of the virus infecting the placental cells, have been examined.

In conclusion, our study revealed that healthy non-infected placentae have elevated levels of CD147 expression and variable levels of ACE2, while TMPRSS2 is present in a very low quantity. Thus, healthy placenta is a non-preferential tissue for SARS-CoV-2 infection. COVID-19 and the presence of virus can up-regulate TMPRSS2, facilitating the virus entry into syncytiotrophoblast and cytotrophoblast cells. We also demonstrate that trophoblast cell lines and endothelial cells are not permissive to virus entry, probably due to a resistance to the fusogenic process or glyocalyx presence respectively. The systemic effect linked to endotheliitis, and therefore development of the preeclampsia-like syndrome in the infected mothers could be due to the direct effect of the spike protein (with its shedding and release) on placental cells, which in turn, can cause increased expression of pro-inflammatory cytokines, increased vascular permeability, and induction of syncytiotrophoblast apoptosis.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving human participants were reviewed and approved by Institutional Review Board of The Maternal-Children’s Hospital Burlo Garofolo. The patients/participants provided their written informed consent to participate in this study.
Author contributions

Conceptualization: CA and RB. Methodology: MT, MS, AB, LZ, and SM. Resources: GZ, AM, TS, FR and FP. Data curation: CA, MT and AB. Writing—original draft preparation: CA, MT and MS. Writing—review and editing: CA, AB, AM, LB, UK and RB. Supervision: LB, SC, MC, GR and RB. Funding acquisition: CA, GR and RB. All authors have read and agreed to the published version of the manuscript. All authors contributed to the article and approved the submitted version.

Funding

This research was supported by Ferring COVID-19 Investigational Grant (GRAVISAR to RB). The funder Ferring Pharmaceuticals was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. This work was supported by the Ministry of Health, Rome - Italy, in collaboration with the Institute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste – Italy (RC24/19 and 47/20 to GR and 09/21 to CA).

Towards an understanding of SARS-CoV-2 infection in pregnancy: A systematic review of 108 pregnancies.

References

1. Varghese PM, Tsolaki AG, Yasin H, Shastri A, Ferluga J, Vatish M, et al. Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. *Immunology* (2020) 225(6):152008. doi: 10.1016/j.imbio.2020.152008

2. Yasmin H, Saha S, Butt MT, Modi RK, George AJT, Kishore U. SARS-CoV-2: Pathogenic mechanisms and host immune response. *Adv Exp Med Biol* (2021) 1313:99–134. doi: 10.1007/978-3-030-67452-6_6

3. Kotlyar AM, Grechukhina O, Chen A, Popkhadze S, Grimslew A, Tal O, et al. Vertical transmission of coronavirus disease 2019: A systematic review and meta-analysis. *Am J Obstet Gynecol* (2021) 224(1):35–53. doi: 10.1016/j.ajog.2020.07.049

4. Alloity J, Chatterjee S, Kew T, Gaetano A, Stallings E, Fernandez-Garcia S, et al. SARS-CoV-2 positivity in pregnancy and timing of mother-to-child transmission: living systematic review and meta-analysis. *BMJ* (2022) 376: e067696. doi: 10.1136/bmj.2021-067696

5. Di Mascio D, Khalil A, Saccone G, Rizzo G, Buca D, Liberati M, et al. Outcome of coronavirus spectrum infections (SARS, MERS, COVID-19) during pregnancy: a systematic review and meta-analysis. *Am J Obstet Gynecol MFM* (2020) 2(2):100107. doi: 10.1016/j.ajogmf.2020.100107

6. Zaigham M, Andersson O. Maternal and perinatal outcomes with COVID-19: A systematic review of 108 pregnancies. *Acta Obstet Gynecol Scand* (2020) 99(7):823–9. doi: 10.1111/aogs.13867

7. Azinheira Nobrega Cruz N, Stoll D, Casarini DE, Bertagnolli M. Role of ACE2 in pregnancy and potential implications for COVID-19 susceptibility. *Clin Sci (Lond)* (2021) 135(15):1805–24. doi: 10.1042/CS20210284

8. Di Toro F, Gjoka M, Di Lorenzo G, De Santo D, De Seta E, Maso G, et al. Impact of COVID-19 on maternal and neonatal outcomes: A systematic review and meta-analysis. *Clin Microbiol Infect* (2022) 27(1):36–46. doi: 10.1016/j.cmi.2020.10.007

9. Metz TD, Clifton RG, Hughes BL, Sandoval GV, Grobman WA, Saade GR, et al. Association of SARS-CoV-2 infection with serious maternal morbidity and mortality from obstetric complications. *JAMA* (2022) 327(8):748–59. doi: 10.1011/jama.2022.1190

10. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: A retrospective review of medical records. *Lancet* (2020) 395(10226):809–15. doi: 10.1016/S0140-6736(20)30360-3

11. Narang K, Emmings EAL, Gunaratne M, Ibirugha ER, Trad ATA, Eleftheri A, et al. SARS-CoV-2 infection and COVID-19 during pregnancy: A multidisciplinary review. *Mayo Clin Proc* (2020) 95(8):1750–65. doi: 10.1016/j.mayocp.2020.05.011

12. Papageorghiou AT, Dertulle P, Gunter RB, Rauch S, Garcia-May PK, Mhatre M, et al. Preeclampsia and COVID-19: Results from the INTERCOVID prospective longitudinal study. *Am J Obstet Gynecol* (2021) 225(3):289 e1–417. doi: 10.1016/j.ajog.2021.05.014

13. Medeiros LT, Paracolli JC, Bannwart-Castro CF, Romao M, Weid IC, Golim MA, et al. Monocytes from pregnant women with pre-eclampsia are polarized to a M1 phenotype. *Am J Reprod Immunol* (2014) 72(1):5–13. doi: 10.1111/aji.12222

14. Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melgozo-Rodriguez L. SARS-CoV-2 infection: The role of cytokines in COVID-19 disease. *Cytokine Growth Factor Rev* (2020) 54:62–75. doi: 10.1016/j.cytogfr.2020.06.001

15. Agostinis C, Mangogna A, Baldiut J, Aghamajidi A, Ricci G, Kishore U, et al. COVID-19, pre-eclampsia, and complement system. *Front Immunol* (2021) 12:775168. doi: 10.3389/fimmu.2021.775168

16. Hoffmann M, Klein-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* (2020) 181(2):271–80 e8. doi: 10.1016/j.cell.2020.02.052

17. Bourgonje AR, Abdulle AE, Timens W, Hillebrands JL, Navis GJ, Goedjijn SJ, et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J Pathol* (2020) 251(3):228–48. doi: 10.1002/path.5471

18. Wang K, Chen W, Zhang Z, Deng Y, Lian JQ, Pu P, et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. *Signal Transduct Target Ther* (2020) 5(1):283. doi: 10.1038/s41392-020-00426-x

19. Luo C, Lai M, Lam K, Leung CO, Pang RT, Chu IK, et al. Identification of CD147 (basigin) as a mediator of trophoblast functions. *Hum Reprod* (2013) 28(11):2920–9. doi: 10.1093/humrep/det355

20. Yurchenko V, Constant S, Bukrinsky M. Dealing with the family: CD147 interactions with cyclophilins. *Immunology* (2006) 117(3):301–9. doi: 10.1111/j.1365-2567.2005.02316.x

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.957224/full#supplementary-material
impaired gestational weight gain and fetal growth restriction.

et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nature* (2021) 594(7861):88–93. doi:10.1038/s41586-021-03434-9

Xiong L, Edwards CK, Zhou L. 3rd. The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature. *Int J Mol Sci* (2021) 15(10):17411–41. doi:10.3390/ijms151017411

Landras A, Reger de Mours C, Joesten S, Eibbe C, Mâœtal S, Mourah S. CD147 is a promising target of tumor progression and a prognostic biomarker. *Cancers* (Basel) (2019) 11(1):1803. doi:10.3390/cancers11111803

Guindolet D, Gibson EE. Role of CD147 (EMMPRIN/Bagasin) in tissue remodeling. *Anat Rec (Hoboken)* (2020) 303(16):1584–9. doi:10.1002/ar.24089

Kouvakas RA. The role of bagasin in reproduction. *Reprod Biol* (2021) 15(4):R97–R109. doi:10.1530/REP-19-0268

Li M, Chen L, Zhang J, Xiong C, Li X. The SARS-CoV-2 receptor ACE2 expression of maternal-fetal interface and fetal organs by single-cell transcriptome study. *PLoS One* (2020) 15(4):e0243209. doi:10.1371/journal.pone.0243209

Singh M, Bansal V, Feschotte C. A single-cell RNA expression map of human coronavirus entry factors. *Cell Rep* (2020) 32(13):108175. doi:10.1016/j.celrep.2020.101875

Dong L, Pei S, Ren Q, Pu S, Yu L, Chen H, et al. Evaluation of vertical transmission of SARS-CoV-2 in utero: Nine pregnant women and their newborns. *Placenta* (2021) 111:91–96. doi:10.1016/j.placenta.2021.06.007

Babal P, Krivovoukova L, Sarvacoa L, Deckow I, Szemes T, Sedlackova T, et al. Intrauterine fetal demise after uncomplicated COVID-19: What can we learn from the case? *Viruses* (2021) 13(12):2545. doi:10.3390/v13122545

Huang Z, Xia S, Mei S, Wen Y, Liu J, Dong C, et al. Integrated analysis reveals the characteristics and effects of SARS-CoV-2 maternal-fetal transmission. *Front Microbiol* (2022) 13:813187. doi:10.3389/fmicb.2022.813187

Mourad M, Jacob T, Sadowski E, Berjano S, Simonne GS, Bagalkot TR, et al. Placental response to maternal SARS-CoV-2 infection. *Sci Rep* (2021) 11(1):14390. doi:10.1038/s41598-021-93931-0

Argouta LB, Lacko LA, Bram Y, Tada T, Carrau L, Rendedor AF, et al. Inflammatory responses in the placenta upon SARS-CoV-2 infection late in pregnancy. *Science* (2022) 255(5042):104223. doi:10.1093/eurheartj/ehaa623

Liu F, Han K, Blair R, Kesten K, Qin Z, Upcin B, et al. SARS-CoV-2 infects endothelial cells in Vivo and in Vitro. *Front Cell Infect Microbiol* (2022) 11:701278. doi:10.3389/fcimb.2021.701278

Schimmel L, Chew KY, Stocke CJ, Yordanov TE, Essbier P, Kulaasinghe A, et al. Endothelial cells are not productively infected by SARS-CoV-2. *Clin Transl Immunol* (2021) 10(10):e1350. doi:10.1002/cti.1350

Rahm MM, Bernier A, Buchrieser J, Schwartz O. The mechanism and consequences of SARS-CoV-2 spike-mediated fusion and syncytia formation. *J Mol Biol* (2022) 434(6):167280. doi:10.1016/j.jmb.2021.167280

Buchrieser J, Degrelle SA, Courdier T, Nevers Q, Manet C, et al. JHMFI proteins inhibit placentocytotrophic formation and promote fetal demise. *Science* (2019) 365(6449):176–80. doi:10.1126/science.aaw7733

Juttukonda L, Wachman EM, Boutet I, Jain M, Benarroch Y, Taglauer ES. Decidual immune response following COVID-19 during pregnancy varies by timing of maternal SARS-CoV-2 infection. *J Reprod Immunol* (2021) 151:103501. doi:10.1016/j.jrepim.2021.103501

Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease. *Eur Heart J* (2020) 41(32):3038–44. doi:10.1093/eurheartj/ehaa623

Poussin A, Montand D, Savale L, Pichon J, Tu L, Parent F, et al. Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)? *Eur Respir J* (2020) 56(1):200634. doi:10.1183/13993003.00634-2020

Agostinis et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. *Nat Rev Immunol* (2021) 21(5):319–29. doi:10.1038/s41577-021-00536-9

Teuwen LA, Geldhof V, Pastus A, Carmelet P. COVID-19: the vasculature unleashed. *Nat Rev Immunol* (2020) 20(7):389–91. doi:10.1038/s41577-020-03434-9